Who is responsible for hiding DEATHS due to O in PEARL Studies?
The best I can tell in the NEJM article, there is one line which hints at DEATHS due to O in the PEARL studies.
There is this line somewhere in the NEJM article:
"In 2 trials of OMONTYS, patients with CKD not on dialysis experienced increased specific cardiovascular events."
Wow, that is not a very clear warning that THIS DRUG CAUSED DEATHS IN PEOPLE WHO WERE NOT ON DIALYSIS and there was no reason for these deaths that was established.
I wonder if this type of wording is some sort of industry-standard double talk, or if AFFY people were intentially trying to downplay the KNOWN DEATHS DUE TO 'O' that occurred in the two Phase 3 trials.
This makes me wonder what was on the minds of AFFY executives.